Tandem Diabetes Care Inc. has reported strong revenue growth and surpassed estimates, but its stock price has declined to a 52-week low due to operational challenges and analyst downgrades.

Tandem Diabetes Care, Inc. is a San Diego-based company that designs and commercializes innovative products for individuals with insulin-dependent diabetes, with a market capitalization of approximately $1.04 billion USD.

Tandem Diabetes Care Inc. reported strong Q1 2025 performance, with record sales growth and revenue exceeding Wall Street estimates, despite missing GAAP EPS estimates.